bellobi.blogg.se - Real ms iconquer ms

#REAL MS ICONQUER MS PLUS#
#REAL MS ICONQUER MS SERIES#

MS patients using fingolimod, a sphingosine-1-phosphate (S1P) receptor modulator, also had lower seroconversion (OR 0.04, 95% CI 0.01-0.12, P<0.001), they wrote in Annals of Neurology.Ī separate study, from Farren Basil Shaw Briggs, PhD, of Case Western Reserve University, in Cleveland, Ohio, and co-authors in Neurology Neuroimmunology and Neuroinflammation, showed that reactions to Covid-19 vaccination within 24 hours of the first shot were reported by 64% of MS patients, and profiles were similar to those of the general population. Overall, patient registries provide the unique patient perspective and has the potential to benefit research, drug development, and patient experiences.Two studies-one in the Annals of Neurology, the other in Neurology Neuroimmunology and Neuroinflammation-examined Covid-19 vaccine response and reactions in people with multiple sclerosis (MS).Ĭompared with MS patients on no disease-modifying therapy, patients using the anti-CD20 monoclonal antibodies ocrelizumab, rituximab, and ofatumumab had lower seroconversion following dose two of vaccination (OR 0.03, 95% CI 0.01-0.06, P<0.001), reported Ruth Dobson, PhD, of Queen Mary University London in England, and co-authors. These registries have also been used in patient-focused drug development and to inform efforts during the COVID-19 pandemic. The symptoms patients ranked with the highest importance are not the ones usually studied in clinical research, highlighting the potential work that can be done and information that can be provided with patient registries. Issues with mobility were ranked lower on the list, but they tend to be most frequently studied in standard clinical research. The top-rated symptoms included fatigue, sleep disturbances, wellbeing, and anxiety. In o ne example involving that registry, data were collected on the symptoms having the greatest impact on patients’ lives.

#REAL MS ICONQUER MS PLUS#

This network is all about “people plus data, and how that can move research forward. This network has a variety of functions - all run by patients, including a governance board, research committee, engagement committee, and others. This registry was created in 2014 and has over 7, 000 participants, all either patients or caregivers affected by MS. McBurney followed his presentation with a registry case example, the iConquer MS patient – powered research network. This step is vital to achieving diversity and representativeness in a registry population. To facilitate patient engagement with registries, one must establish trust with communities and involve patients in the development of the registr y and corresponding studies.

Registries can collect information on individuals with a particular disease, follow disease progression, document patient experience and preference, and even can be used as surveillance tools to monitor quality of care and safety. Source: AHRQ Effective Health Care ProgramĬ reat ing a patient registry, starts with defin ing its purpose and identifying the patient community and types of RWD that will be collected.

M ay also be referred to as clinical registries, disease registries, and outcomes registries.

C ompiled to learn about that disease or condition, monitor outcomes and quality of care, or to develop research or therapeutics.

An organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves a predetermined scientific, clinical, or policy purpose(s).

The Agency for Healthcare Research and Quality’s (AHRQ) defines patient registr ies as : T here is no single, standardized, agreed – upon definition as the complexity of registries varies greatly – ranging from simple surveys to sophisticated, linked datasets. The term “p atient registr y” is sometimes used interchangeably with clinical registr y, disease registr y, and outcomes registr y. Speakers included Robert McBurney, PhD, Chief Research Officer, Accelerated Cure Project for Multiple Sclerosis and Vanessa Boulanger, MSc, Director of Research Programs, National Organization for Rare Disorders.

#REAL MS ICONQUER MS SERIES#

The National Health Council and the Duke-Margolis Center for Health Policy continued the introductory series on real- world data (RWD) and real-world evidence (RWE) with a webinar introducing patient registries, which are made up of RWD and often inform RWE studies. By Sara Gray, Associate, Research & Programs